Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 15, Issue 1, 2005, Pages 24-30

  De Simone, Giovanni ^a   Romano, Carmela ^a   De Caprio, Carmela ^a   Contaldo, Franco ^a   Salanitri, Tommaso ^b   Di Luzio Paparatti, Umberto ^b   Pasanisi, Fabrizio ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b ABBOTT DIAGNOSTICS   (Italy)

Author keywords

Body mass index; Cardiac structure; Double blind randomized trial; Treatment

Indexed keywords

SIBUTRAMINE;

ADULT; AGED; ARM; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DECELERATION; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; GEOMETRY; HEART LEFT VENTRICLE WALL; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE RELAXATION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEART VALVE; HEART VOLUME; HEMODYNAMICS; HUMAN; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; OBESITY; PATIENT SELECTION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 17444400106     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2004.07.002     Document Type: Article

References (34)

1. Seidell JC. Obesity in Europe: scaling an epidemic, Int J Obes Relat Metab Disord 1995;19(Suppl. 3):S1-4.
2. de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994;23(5):600-6.
3. Alpert MA, Lambert CR, Terry BE, Kelly DL, Panayiotou H, Mukerji V, et al. Effect of weight loss on left ventricular mass in nonhypertensive morbidly obese patients. Am J Cardiol 1994;73(12):918-21.
4. Balkestein EJ, Aggel-Leijssen DP, van Baak MA, Struijker-Boudier HA, Van Bortel LM. The effect of weight loss with or without exercise training on large artery compliance in healthy obese men. J Hypertens 1999;17(12 Pt 2):1831-5.
5. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R, Georgiades A, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000;160(13): 1947-58.
6. de Leiva A. What are the benefits of moderate weight loss? Exp Clin Endocrinol Diabetes 1998;106(Suppl. 2): 10-3.
7. de Simone G, Mancini M, Mainenti G, Turco S, Ferrara LA. Weight reduction lowers blood pressure independently of salt restriction. J Endocrinol Invest 1992;15(5):339-43.
8. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7(2):189-98.
9. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med 1997;337(9):581-8.
10. Palmieri V, Arnett DK, Roman MJ, Liu JE, Bella JN, Oberman A, et al. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. Am J Med 2002;112(9):710-5.
11. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102(23):2836-41.
12. Celada P, Martin F, Artigas F. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 1994;55(15):1237-43.
13. Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 2000;85(7):913-5. A10.
14. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Wood EA, Howard BV, et al. Relations of Doppler stroke volume and its components to left ventricular stroke volume in normotensive and hypertensive American Indians: the strong heart study. Am J Hypertens 1997; 10(6):619-28.
15. de Simone G, Mureddu GF, Greco R, Scalfi L, Del Puente AE, Franzese A, et al. Relations of left ventricular geometry and function to body composition in children with high casual blood pressure. Hypertension 1997; 30(3 Pt 1):377-82.
16. de Simone G, Greco R, Mureddu G, Romano C, Guida R, Celentano A, et al. Relation of left ventricular diastolic properties to systolic function in arterial hypertension. Circulation 2000;101(2):152-7.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58(6):1072-83.
18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux RB, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2(5):358-67.
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57(6):450-8.
20. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20(5):1251-60.
21. Dubin J, Wallerson DC, Cody RJ, Devereux RB. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J 1990; 120(1):116-23.
22. Mureddu GF, de Simone G, Greco R, Rosato GF, Contaldo F. Left ventricular filling in arterial hypertension. Influence of obesity and hemodynamic and structural confounders. Hypertension 1997;29(2):544-50.
23. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106(2):179-84.
24. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68(6):1180-6.
25. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999;126(6):1487-95.
26. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity, Int J Obes Relat Metab Disord 2000;24(2):144-50.
27. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144(3):508-15.
28. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000;160(14):2185-91.
29. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females, Int J Obes Relat Metab Disord 1999;23(10):1009-15.
30. Dessi-Fulgheri P, Sarzani R, Serenelli M, Tamburrini P, Spagnolo D, Giantomassi L, et al. Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension 1999;33(2):658-62.
31. Alpert MA, Terry BE, Kelly DL. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am J Cardiol 1985;55(6):783-6.
32. Fagerberg B, Berglund A, Andersson OK, Berglund G, Wikstrand J. Cardiovascular effects of weight reduction versus antihypertensive drug treatment: a comparative, randomized, 1-year study of obese men with mild hypertension. J Hypertens 1991;9(5):431-9.
33. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, Ikeda M. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. Am Heart J 1996; 131(2):313-9.
34. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993; 88(4 Pt 1):1444-55.